ZA200208014B - Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties. - Google Patents

Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties. Download PDF

Info

Publication number
ZA200208014B
ZA200208014B ZA200208014A ZA200208014A ZA200208014B ZA 200208014 B ZA200208014 B ZA 200208014B ZA 200208014 A ZA200208014 A ZA 200208014A ZA 200208014 A ZA200208014 A ZA 200208014A ZA 200208014 B ZA200208014 B ZA 200208014B
Authority
ZA
South Africa
Prior art keywords
mmol
equiv
reaction mixture
solution
concentrated
Prior art date
Application number
ZA200208014A
Other languages
English (en)
Inventor
Srikanth Venkatraman
Ashok Arasappan
Viyyoor M Girijavallabhan
Brian A Mckittrick
Vincent S Madison
Kevin X Chen
F George Njoroge
Tin-Yau Chan
Andrew J Prongay
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ZA200208014B publication Critical patent/ZA200208014B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA200208014A 2000-04-19 2002-10-04 Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties. ZA200208014B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19820400P 2000-04-19 2000-04-19

Publications (1)

Publication Number Publication Date
ZA200208014B true ZA200208014B (en) 2004-02-12

Family

ID=22732422

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200208014A ZA200208014B (en) 2000-04-19 2002-10-04 Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties.

Country Status (22)

Country Link
US (1) US6914122B2 (enExample)
EP (1) EP1274724A2 (enExample)
JP (1) JP4748912B2 (enExample)
KR (1) KR20020097220A (enExample)
CN (3) CN101580536A (enExample)
AR (1) AR030558A1 (enExample)
AU (1) AU2001253621A1 (enExample)
BR (1) BR0110104A (enExample)
CA (1) CA2406532A1 (enExample)
CZ (1) CZ20023473A3 (enExample)
HK (1) HK1048479A1 (enExample)
HU (1) HUP0302957A2 (enExample)
IL (1) IL151935A0 (enExample)
MX (1) MXPA02010375A (enExample)
NO (1) NO20025030L (enExample)
NZ (1) NZ521456A (enExample)
PE (1) PE20011288A1 (enExample)
PL (1) PL358591A1 (enExample)
RU (1) RU2002131163A (enExample)
SK (1) SK14952002A3 (enExample)
WO (1) WO2001081325A2 (enExample)
ZA (1) ZA200208014B (enExample)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2268391A1 (en) * 1996-10-18 1998-04-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
MXPA03005219A (es) * 2000-12-12 2003-09-25 Schering Corp Peptidos diarilicos como inhibidores de ns3-serina proteasa en hepatitis de virus c.
DZ3487A1 (fr) 2001-01-22 2002-07-25 Merck Sharp & Dohme Derives de nucleoside comme inhibiteurs de l'arn polymerase virale d'arn-dependant
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
KR20040099425A (ko) * 2002-04-11 2004-11-26 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 c형 간염 바이러스 ns3-ns4프로테아제의 억제제
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
PT1654261E (pt) 2003-05-21 2008-01-18 Boehringer Ingelheim Int Compostos inibidores da hepatite c
US7476653B2 (en) * 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US20090198050A1 (en) * 2003-06-18 2009-08-06 Tranzyme Pharma Inc. Macrocyclic Modulators of the Ghrelin Receptor
US8921521B2 (en) 2003-06-18 2014-12-30 Ocera Therapeutics, Inc. Macrocyclic modulators of the Ghrelin receptor
CA2528375C (en) 2003-06-18 2013-11-19 Tranzyme Pharma, Inc. Macrocyclic antagonists of the motilin receptor
EP1664090A2 (en) 2003-08-26 2006-06-07 Schering Corporation Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus
PE20050374A1 (es) * 2003-09-05 2005-05-30 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
RS20060197A (sr) 2003-09-22 2008-09-29 Boehringer Ingelheim International Gmbh., Makrociklični peptidi koji su aktivni protiv hepatitisa c virusa
CN1894274A (zh) 2003-09-26 2007-01-10 先灵公司 丙肝病毒ns3丝氨酸蛋白酶的大环抑制剂
KR20120010278A (ko) 2003-10-10 2012-02-02 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 hcv ns3-ns4a 프로테아제의 억제제
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
WO2005043118A2 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Drug discovery method
MXPA06005683A (es) 2003-11-20 2006-12-14 Schering Corp Inhibidores despeptidizados de la proteasa ns3 del virus de la hepatitis c.
DE602005025855D1 (de) 2004-01-21 2011-02-24 Boehringer Ingelheim Pharma Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus
WO2005077969A2 (en) 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US7816326B2 (en) 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
HRP20100416T1 (hr) 2004-02-27 2010-09-30 Schering Corporation Sumporni spojevi kao inhibitori serinske proteaze ns3 virusa hepatitisa c
KR20060124725A (ko) 2004-02-27 2006-12-05 쉐링 코포레이션 C형 간염 바이러스 ns3 프로테아제의 억제제
KR20060127162A (ko) 2004-02-27 2006-12-11 쉐링 코포레이션 C형 간염 바이러스 ns3 세린 프로테아제의 억제제로서의화합물
TW200529823A (en) 2004-02-27 2005-09-16 Schering Corp Novel compounds as inhibitors of hepatitis C virus NS3 serine protease
US7342041B2 (en) 2004-02-27 2008-03-11 Schering Corporation 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis C virus NS3 serine protease
WO2005113581A1 (en) 2004-05-20 2005-12-01 Schering Corporation Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease
JP4914355B2 (ja) 2004-07-20 2012-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング C型肝炎インヒビターペプチド類似体
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
JP2008511633A (ja) 2004-08-27 2008-04-17 シェーリング コーポレイション C型肝炎ウィルスns3セリンプロテアーゼの阻害因子としてのアシルスルホンアミド化合物
WO2007001406A2 (en) * 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
US20070237818A1 (en) * 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
WO2006130686A2 (en) 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors in combination with food
NZ563365A (en) * 2005-06-02 2011-02-25 Schering Corp Combination of HCV protease inhibitors with a surfactant
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
EP1924594A2 (en) 2005-07-25 2008-05-28 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
RU2436787C2 (ru) * 2005-07-29 2011-12-20 Тиботек Фармасьютикалз Лтд. Макроциклические ингибиторы вируса гепатита с
EP2402331A1 (en) * 2005-08-02 2012-01-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
ATE463480T1 (de) 2005-08-19 2010-04-15 Vertex Pharma Verfahren und zwischenprodukte
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
KR20080056295A (ko) 2005-10-11 2008-06-20 인터뮨, 인크. C형 간염 바이러스 복제를 억제하기 위한 화합물 및 방법
US7705138B2 (en) * 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
EP2392588A3 (en) 2005-11-11 2012-03-07 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
JP5436864B2 (ja) 2006-02-27 2014-03-05 バーテックス ファーマシューティカルズ インコーポレイテッド Vx−950を含む共結晶体およびそれを含む医薬組成物
CA2646229A1 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
WO2007111866A2 (en) * 2006-03-23 2007-10-04 Schering Corporation Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
RU2008152171A (ru) * 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
AU2007284027A1 (en) 2006-08-17 2008-02-21 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2008048121A2 (en) 2006-10-18 2008-04-24 Lincoln University Macrocyclic cysteine protease inhibitors and compositions thereof
KR20090094154A (ko) 2006-12-22 2009-09-03 쉐링 코포레이션 Hcv 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체
MX2009006877A (es) 2006-12-22 2009-09-28 Schering Corp Derivados indolicos con anillo unido en las posiciones 5,6 y metodos de uso de los mismos.
WO2008082488A1 (en) * 2006-12-22 2008-07-10 Schering Corporation 4, 5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
WO2008106058A2 (en) 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
KR20090115970A (ko) 2007-02-27 2009-11-10 버텍스 파마슈티칼스 인코포레이티드 공-결정 및 그를 포함하는 제약 조성물
BRPI0811020A2 (pt) * 2007-05-03 2015-07-21 Intermune Inc Composto, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática, de intensificação da função hepática em indivíduo com infecção do vírus da hepatite c e métodos de síntese de compostos, de administração de inibidor da infecção do vírus da hepatite c (hcv) e de distribuição de forma de dosagem oral.
CN102872461A (zh) 2007-05-04 2013-01-16 弗特克斯药品有限公司 用于治疗hcv感染的组合治疗
AR066528A1 (es) * 2007-05-10 2009-08-26 Array Biopharma Inc Peptidos inhibidores de la replicacion del virus de la hepatitis c
US8242140B2 (en) 2007-08-03 2012-08-14 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
AR068107A1 (es) * 2007-08-29 2009-11-04 Schering Corp Derivados indolicos 2,3 sustituidos y una composicion farmaceutica
CN101821252A (zh) * 2007-08-29 2010-09-01 先灵公司 取代的吲哚衍生物及其使用方法
PE20090994A1 (es) * 2007-08-29 2009-08-03 Schering Corp Derivados de azaindol 2,3-sustituidos como agentes antivirales
CN101835774B (zh) 2007-08-30 2014-09-17 弗特克斯药品有限公司 共晶体和包含该共晶体的药物组合物
GB0718575D0 (en) 2007-09-24 2007-10-31 Angeletti P Ist Richerche Bio Nucleoside derivatives as inhibitors of viral polymerases
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
CN102099351A (zh) * 2007-11-16 2011-06-15 先灵公司 3-杂环取代的吲哚衍生物及其使用方法
CA2705587A1 (en) * 2007-11-16 2009-05-22 Schering Corporation 3-aminosulfonyl substituted indole derivatives and methods of use thereof
KR20100098534A (ko) 2007-12-19 2010-09-07 베링거 인겔하임 인터내셔날 게엠베하 바이러스 폴리머라제 억제제
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
AU2008340261C1 (en) * 2007-12-21 2015-12-10 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8309685B2 (en) * 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
WO2009082697A1 (en) * 2007-12-21 2009-07-02 Avila Therapeutics, Inc. Hcv protease inhibitors and uses thereof
AU2009210789B2 (en) 2008-02-04 2014-01-30 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
CA2705300A1 (fr) * 2008-02-15 2009-06-04 Xeda International Macrocyclic inhibitors of hepatitis c protease
WO2009117594A1 (en) 2008-03-20 2009-09-24 Enanta Pharmaceuticals, Inc. Fluorinated macrocyclic compounds as hepatitis c virus inhibitors
AP2010005416A0 (en) * 2008-04-15 2010-10-31 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication.
MX2010013630A (es) * 2008-06-13 2010-12-21 Schering Corp Derivados triciclicos de indol y metodos de uso de los mismos.
EP2326626B1 (en) 2008-08-20 2013-10-16 Merck Sharp & Dohme Corp. Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AU2009282572B2 (en) 2008-08-20 2014-09-11 Merck Sharp & Dohme Corp. Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AR072940A1 (es) 2008-08-20 2010-09-29 Schering Corp Derivados de piridina y pirimidina sustituidos con etinilo y su uso en el tratamiento de infecciones virales
TWI409265B (zh) 2008-08-20 2013-09-21 Merck Sharp & Dohme 經取代之吡啶及嘧啶衍生物及彼等於治療病毒感染之用途
US20100173837A1 (en) 2009-01-07 2010-07-08 Scynexis, Inc. Dosing forms and regimens comprising 3-[(r)-2-(n,n-dimethylamino)ethylthio-sar]-4-(gammahydroxymethylleucine)cyclosporine
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
WO2010101967A2 (en) 2009-03-04 2010-09-10 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole hcv polymerase inhibitors
WO2010118078A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8980920B2 (en) 2009-05-29 2015-03-17 Merck Sharp & Dohme Corp. Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C
JP2013501068A (ja) 2009-08-05 2013-01-10 アイディニックス ファーマシューティカルズ インコーポレイテッド 大環状セリンプロテアーゼ阻害剤
EP2470189A4 (en) 2009-08-27 2013-01-23 Merck Sharp & Dohme METHOD FOR PRODUCING PROTEASE INHIBITORS OF HEPATITIS C VIRUS
CN102741270B (zh) * 2009-09-28 2015-07-22 英特穆恩公司 C型肝炎病毒复制的环肽抑制剂
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
US20120276047A1 (en) 2009-11-25 2012-11-01 Rosenblum Stuart B Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
CN102822175A (zh) 2009-12-18 2012-12-12 埃迪尼克斯医药公司 5,5-稠合的亚芳基或亚杂芳基丙型肝炎病毒抑制剂
AU2010341537A1 (en) 2009-12-22 2012-08-09 Merck Sharp & Dohme Corp. Fused Tricyclic Compounds and methods of use thereof for the treatment of viral diseases
US9433621B2 (en) 2010-02-18 2016-09-06 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8609635B2 (en) 2010-03-09 2013-12-17 Merck Sharp & Dohme Corp. Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
WO2011156337A2 (en) * 2010-06-07 2011-12-15 Abbott Laboratories Macrocyclic hepatitis c serine protease inhibitors
CA2805440A1 (en) 2010-07-26 2012-02-09 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
CA2812779A1 (en) 2010-09-29 2012-04-19 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
EP2489669A1 (en) * 2011-02-18 2012-08-22 Helmholtz-Zentrum für Infektionsforschung GmbH Haprolid and derivatives thereof as inhibitors of HCV
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
JP2014515023A (ja) 2011-04-13 2014-06-26 メルク・シャープ・アンド・ドーム・コーポレーション 2’−置換ヌクレオシド誘導体およびウイルス疾患の処置のためのその使用方法
WO2012142075A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
US20140378416A1 (en) 2011-09-14 2014-12-25 Michael P. Dwyer Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
EP3974563A1 (en) * 2011-12-28 2022-03-30 Chugai Seiyaku Kabushiki Kaisha Cyclic peptides
WO2014110296A1 (en) * 2013-01-09 2014-07-17 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
EP3046924A1 (en) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015065817A1 (en) 2013-10-30 2015-05-07 Merck Sharp & Dohme Corp. Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
HUE059925T2 (hu) 2015-03-13 2023-01-28 Chugai Pharmaceutical Co Ltd Módosított aminoacil-tRNS-szintetáz és alkalmazása
US12391971B2 (en) 2017-01-31 2025-08-19 Chugai Seiyaku Kabushiki Kaisha Method for synthesizing peptides in cell-free translation system
CN118772227A (zh) 2017-06-09 2024-10-15 中外制药株式会社 用于合成含有n-取代氨基酸的肽的方法
EP3694508A4 (en) 2017-10-11 2021-11-24 Cornell University MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS
WO2019117274A1 (ja) 2017-12-15 2019-06-20 中外製薬株式会社 ペプチドの製造方法、及び塩基の処理方法
JP7279073B2 (ja) 2018-11-07 2023-05-22 中外製薬株式会社 O-置換セリン誘導体の製造方法
WO2020111238A1 (ja) 2018-11-30 2020-06-04 中外製薬株式会社 ペプチド化合物、またはアミド化合物の脱保護法および固相反応における脱樹脂方法、並びにペプチド化合物の製造方法
CN113692401A (zh) 2019-03-15 2021-11-23 中外制药株式会社 芳香族氨基酸衍生物的制备方法
US20230151060A1 (en) 2019-11-07 2023-05-18 Chugai Seiyaku Kabushiki Kaisha Cyclic peptide compound having kras inhibitory action

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5377083A (en) * 1976-12-16 1978-07-08 Asahi Chem Ind Co Ltd Penicillins and their derivatives
US4260601A (en) * 1979-10-23 1981-04-07 Nyegaard & Co. A/S Chemical compounds
ZA838780B (en) * 1982-11-26 1985-01-30 Nyegaard & Co As Peptide compounds
US4956344A (en) * 1987-09-17 1990-09-11 Hafslund Nycomed A/S Method for treatment of lesions in the large intestinal epithelium with a tripeptide
WO1989004669A1 (en) 1987-11-18 1989-06-01 Chiron Corporation Nanbv diagnostics and vaccines
DK0381216T3 (da) 1989-02-01 1996-05-13 Asahi Glass Co Ltd Azeotrop eller azeotroplignende chlorfluorcarbonhydridblanding
ES2219637T3 (es) 1990-04-04 2004-12-01 Chiron Corporation Proteasa del virus de la hepatitis c.
JPH07228594A (ja) * 1994-02-18 1995-08-29 Suntory Ltd エンドセリン受容体拮抗ペプチド
IL109943A (en) * 1994-06-08 2006-08-01 Develogen Israel Ltd Conformationally constrained backbone cyclized peptide analogs
AU4156197A (en) 1996-08-21 1998-03-06 Hybridon, Inc. Oligonucleotide prodrugs
CA2268391A1 (en) 1996-10-18 1998-04-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
IL134233A0 (en) * 1997-08-11 2001-04-30 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptide analogues
CN1163504C (zh) * 1998-04-15 2004-08-25 阿温蒂斯药物公司 制备与树脂结合的环状肽的方法
GB9812523D0 (en) * 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) * 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6407066B1 (en) * 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4

Also Published As

Publication number Publication date
NO20025030D0 (no) 2002-10-18
JP4748912B2 (ja) 2011-08-17
MXPA02010375A (es) 2003-04-25
KR20020097220A (ko) 2002-12-31
HK1048479A1 (zh) 2003-04-04
CN1432022A (zh) 2003-07-23
WO2001081325A3 (en) 2002-08-01
JP2003531199A (ja) 2003-10-21
AU2001253621A1 (en) 2001-11-07
NO20025030L (no) 2002-12-18
HUP0302957A2 (hu) 2003-12-29
BR0110104A (pt) 2003-01-07
IL151935A0 (en) 2003-04-10
WO2001081325A2 (en) 2001-11-01
US20020016294A1 (en) 2002-02-07
EP1274724A2 (en) 2003-01-15
PL358591A1 (en) 2004-08-09
CN1935833A (zh) 2007-03-28
PE20011288A1 (es) 2001-12-12
SK14952002A3 (sk) 2003-03-04
RU2002131163A (ru) 2004-06-27
NZ521456A (en) 2004-07-30
CA2406532A1 (en) 2001-11-01
CZ20023473A3 (cs) 2003-01-15
CN101580536A (zh) 2009-11-18
AR030558A1 (es) 2003-08-27
US6914122B2 (en) 2005-07-05

Similar Documents

Publication Publication Date Title
ZA200208014B (en) Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties.
CA2410662C (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
US6800434B2 (en) Peptides as NS3-serine protease inhibitors of hepatitis C virus
US7169760B2 (en) Peptides as NS3-serine protease inhibitors of hepatitis C virus
AU2009210423B2 (en) Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
US20020068702A1 (en) Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
AU2001276988A1 (en) Peptides as NS3-serine protease inhibitors of hepatitis C virus
WO2002008198A2 (en) Novel imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus
AU2001280637B2 (en) Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
AU2001280637A1 (en) Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
HK1058047B (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus